Blood Group Systems Explained: ABO and Rh Compatibility, Hemolytic Risk, Transfusion Safety, and Typing Methods

Blood group systems are genetically determined classifications of surface antigens and corresponding antibodies on red blood cells (RBCs). Clinically, the two most consequential systems are ABO and the Rhesus (Rh) system, because they strongly influence transfusion compatibility, pregnancy outcomes, and the risk of immune-mediated hemolysis.

ABO blood grouping is based on antigens on RBC membranes. People with type A blood express A antigen and typically have anti-B antibodies in plasma. Type B expresses B antigen and has anti-A antibodies. Type AB expresses both A and B antigens and usually lacks naturally occurring anti-A and anti-B antibodies. Type O expresses neither A nor B antigens but usually has both anti-A and anti-B antibodies. These antibodies are largely immunoglobulin M (IgM) and can rapidly activate complement, making ABO-incompatible transfusions particularly dangerous.

The Rh system is dominated by the D antigen. Individuals who are Rh-positive (RhD+) express D antigen; Rh-negative (RhD−) do not. Importantly, RhD– individuals may develop anti-D antibodies after exposure to RhD+ RBCs, such as through transfusion or pregnancy. While Rh incompatibility is often less immediate than ABO mismatch, it can produce clinically significant hemolytic reactions and hemolytic disease of the fetus and newborn (HDFN).

Transfusion reactions occur when donor RBC antigens are recognized by recipient antibodies. The most severe immediate hemolytic transfusion reaction (IHTR) is typically due to ABO incompatibility, leading to rapid complement activation, intravascular hemolysis, and release of free hemoglobin. This can trigger hypotension, fever, flank pain, hemoglobinuria, disseminated intravascular coagulation (DIC), acute kidney injury, and shock. Non-ABO antibody incompatibilities (including Rh antibodies such as anti-E, anti-c, or anti-Kell) may cause delayed hemolytic transfusion reactions, characterized by post-transfusion hemoglobin drop, positive antibody screens, and reticulocytosis days to weeks later.

To prevent these outcomes, modern blood banking relies on systematic testing: forward typing, reverse typing, antibody screening, and crossmatching. Forward typing detects A and B antigens on the patient RBCs using reagent antisera. Reverse typing tests for anti-A and anti-B antibodies in the patient serum by reacting serum with known reagent RBCs. Concordance confirms the ABO type. Antibody screening uses reagent cells with known antigen profiles to identify unexpected alloantibodies. Crossmatching assesses compatibility between donor RBCs and recipient serum, detecting both major and clinically significant minor antibodies. In high-risk cases, especially in patients with previous transfusions, pregnancies, or hematologic disorders, extended phenotype or genotype matching may be used to reduce alloimmunization.

Pregnancy introduces additional immune dynamics. If an RhD− pregnant person carries an RhD+ fetus, fetal RBCs can enter maternal circulation during delivery or bleeding events, stimulating maternal anti-D antibody formation. In a subsequent RhD+ pregnancy, these maternal IgG antibodies cross the placenta and can opsonize fetal RBCs, causing HDFN. Prophylaxis with anti-D immunoglobulin (RhIg) during appropriate gestational windows and after sensitizing events dramatically reduces maternal alloimmunization and prevents most cases of severe HDFN.

Beyond ABO and Rh, multiple other blood group antigens exist (e.g., Kell, Duffy, Kidd, MNS). Some are capable of causing alloimmunization and hemolysis. For example, anti-Kell antibodies can suppress erythropoiesis in the fetus, sometimes leading to significant anemia even with lower hemoglobin destruction. Because antibody specificity and strength vary, careful antibody identification and antigen matching are essential, particularly for chronically transfused patients.

Blood typing is also relevant in clinical emergencies, where the priority is rapid stabilization while minimizing risk. Emergency release protocols typically use uncrossmatched RBC units with the best available compatibility, often O-negative or group-specific RBCs, then transition to definitive testing as soon as possible.

In summary, blood group systems are not merely labels; they reflect immune recognition between donor and recipient. ABO incompatibility primarily drives immediate complement-mediated hemolysis through preformed antibodies, while Rh (and other minor systems) largely affect delayed hemolysis and HDFN through sensitization and IgG alloantibodies. Reliable transfusion safety depends on accurate typing, antibody screening, and crossmatching, with RhIg prophylaxis playing a central role in preventing Rh-mediated pregnancy complications.

Source: @demorinotema